June 17, 2021 / Community

PPMD Virtual Conference to Feature 5 Late-Breaking News Sessions

PPMD’s 2021 Virtual Annual Conference to Feature Five Late-Breaking News Sessions

We are excited to share that five Industry Partners will be announcing newly released data to the Duchenne community for the first time during PPMD’s 2021 Virtual Annual Conference, June 23-26. Partners that will be presenting new data to the community are: NS Pharma, PTC Therapeutics, FibroGen, Italfarmaco and ReveraGen (partnership with Santhera).

NS Pharma

Dr. Paula Clemens will present functional long term data from NS Pharma’s Clinical Trial for Viltolarsen in Duchenne patients on Wednesday, 6/23 at 8:00 PM ET.

PTC Therapeutics

Dr. Craig McDonald will present PTC’s updated data on Deflazacort versus prednisone regimens in patients with Duchenne on Thursday, 6/24 at 7:39 PM ET.


Bassem Elmankabadi, M.D., Executive Medical Director, Clinical Development at FibroGen, will present the Phase II Study results from the Pamrevlumab 079 trial (Mission Study) in patients with non-ambulatory Duchenne muscular dystrophy on Friday, 6/25 at 7:47 PM ET.


Dr. Paolo Bettica, Italfarmaco, will present the Phase II Study results from the Givinostat trial in patients with Becker on Saturday, 6/26 at 1:05 PM ET.

ReveraGen (partnership with Santhera)

Dr. Eric Hoffman, ReveraGen (partnership with Santhera), will present the topline results with Vamorolone in the Pivotal VISION-DMD Study on Saturday, 6/26 at 3:00 PM ET.

Additional Highlights

In addition to these presentations, PPMD’s 2021 Virtual Annual Conference will feature dedicated updates from 20 industry partners currently in clinical trials, with clear and concise information regarding various therapeutic approaches.

We also look forward to sharing in-depth interviews with key opinion leaders, and providing families with opportunities to schedule one-on-one appointments with experts, including PPMD’s genetic counselors as well as other educational and behavioral health experts. These appointments can be used to discuss genetic test reports and inform you of the clinical trials, research studies, and approved therapies that may benefit you or your child.

Register today

The community is excited to hear these updates for the first time at the largest annual global gathering of Duchenne and Becker families.

Over 25 years ago, PPMD began convening the Duchenne community annually, to share knowledge, ensure the patient voice was at the center of the conversation, and galvanize the Duchenne space.

Each year, the community gathers to hear updates from trial sponsors, clinical care providers, researchers, and each other. Now in its 27th year (and second virtual year), PPMD expects close to 2,000 attendees for four days packed full of informative and interactive sessions.

If you haven’t registered for PPMD’s 2021 Virtual Annual Conference — what are you waiting for? Check out our full agenda and register today!

View the PPMD 2020 Virtual Annual Conference schedule & directory.

Join Our Mailing List